Mustang Bio, Inc. (“Mustang”) is a clinical-stage biopharmaceutical company focused on translating today’s
medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors
and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise
acquiring an ownership interest, to fund research and development, and to outlicense or bring the
technologies to market. Mustang has partnered with top medical institutions to advance the development of
CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as a lentiviral gene therapy
for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic
reports with the U.S. Securities and Exchange Commission. Mustang was founded by Fortress Biotech, Inc.
(NASDAQ: FBIO).